Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.57 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30319896 | 1.00 | TYR (0.58) | TYRITGB3ITGA2BITGAVTACR1 | |
| SCHEMBL9744805 | 1.00 | TYR (0.58) | TYRITGB3ITGA2BITGAVTACR1 | |
| SCHEMBL29559972 | 0.92 | TYR (0.62) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL7437357 | 0.92 | TYR (0.62) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL5802843 | 0.92 | TYR (0.62) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL2947377 | 0.90 | LCK (0.61) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL17294499 | 0.89 | CA2 (0.57) | TYRITGB3ITGA2BITGAVTACR1 | |
| SCHEMBL8586541 | 0.89 | FOLH1 (0.58) | TYRITGB3ITGA2BITGAVTACR1 | |
| SCHEMBL8586533 | 0.89 | ITGB3 (0.57) | TYRITGB3ITGA2BITGAVTACR1 | |
| SCHEMBL7296176 | 0.88 | TYR (0.55) | TYRITGB3ITGAVTACR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127167-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-04-24 | — | — | US | claimed |
| EP-4401555-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-07-24 | — | — | EP | claimed |
| WO-2023042201-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-23 | — | — | WO | claimed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250127167-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-04-24 | — | — | US | disclosed |
| CN-119176768-A | Preparation method and application of catechol derivatives and administration and preparation device | 海南大学 | 2024-12-24 | — | — | CN | disclosed |
| EP-4401555-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-07-24 | — | — | EP | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| CN-109963870-B | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4966915-A | L-dopa derivatives or their acid addition salts, process for producing same and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| EP-0309827-A1 | L-Dopa derivatives or their acid addition salts, process for producing same and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
| EP-0268678-A1 | NOVEL 5-FLUOROURIDINE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | FUJI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1988-06-01 | — | — | EP | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
| US-3933859-A | BLOOD PRESSURE LOWERING, SYMPATHECTOMY | HOFFMANN-LA ROCHE, INC. (US) | 1976-01-20 | — | — | US | disclosed |
| US-3846476-A | N-BENZYLOXYCARBONYL-DOPA DERIVATIVES | HOFFMANN LA ROCHE | 1974-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | TYR 3490/4885ITGB3 626/4885ITGA2B 908/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | TYR 4528/4885ITGB3 1899/4885ITGA2B 1865/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | TYR 4528/4885ITGB3 1899/4885ITGA2B 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.